1[1]Nakamura K, Inkuchi K, Dan K. Abnormalities of the P53, N-ras, DCC and FLT-3 genes in myelodysplastic syndromes, J Nippon Med School, 2001, 68: 143-148.
2[2]Christiansen D H, Andersen M K, Pedersen-Bjergaad J. Mutations with loss of heterozygosity of P53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol, 2001, 19:1405-1413.
3[3]Souza Fernandez T, Menezes de Souza J, Macedo Silva M L, et al. Correlation of N-ras point mutations with specific chromosomal abnormalities in primary myelodysplastic synrome. LeukRes, 1998, 22:125-134.
4[4]Tamiya S, Etoh K, Suzushima H, et al. Mutation of CD95 (Fas/Apo-1)gene in adult T-cell Leukemia cells.Blood, 1998, 91:3935-3942.
5[5]Gupta P, Niehans G A, LeRoy S C, et al. Fas ligand expression in the bone marrow in mylodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia, 1999, 13:44-53.
6[6]Lepelley P, Grardel N, Erny O, et al. Fas/APO-1(CD95) expression in myelodysplastic syndromes. Leuk lymphoma, 1998, 30:307-312.
7[7]Parker J E, Mufti G J, Rasool F, et al. The vole of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood, 2000, 96:3932-3938.
9[9]Chehab N H, Malikzay A, Appel M, et al. Chk2/hCdsl functions as a DNA damage checkpoint in G(1)by stabilizing P53. Genes Dev, 2000, 14:278-288.
10[10]Tsabouri S E, Georgioll I, Alamanos I, et al. Increased prevalence of gstm (1) null genotype in patients with myelodysplastic syndrome: A case-control study. Acta Haematol, 2000, 104:169-173.
